首页> 美国卫生研究院文献>Pharmaceutics >Modulation of the Release of a Non-Interacting Low Solubility Drug from Chitosan Pellets Using Different Pellet Size Composition and Numerical Optimization
【2h】

Modulation of the Release of a Non-Interacting Low Solubility Drug from Chitosan Pellets Using Different Pellet Size Composition and Numerical Optimization

机译:使用不同颗粒尺寸组成和数值优化方法调节壳聚糖微丸中非相互作用低溶解度药物的释放

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Two size classes of piroxicam (PXC) pellets (mini (380–550 μm) and conventional (700–1200 μm)) were prepared using extrusion/spheronization and medium viscosity chitosan (CHS). Mixture experimental design and numerical optimization were applied to distinguish formulations producing high sphericity pellets with fast or extended release. High CHS content required greater wetting liquid volume for pellet formation and the diameter decreased linearly with volume. Sphericity increased with CHS for low-to-medium drug content. Application of PXRD showed that the drug was a mixture of form II and I. Crystallinity decreased due to processing and was significant at 5% drug content. Raman spectroscopy showed no interactions. At pH 1.2, the dissolved CHS increased ‘apparent’ drug solubility up to 0.24 mg/mL while, at pH 5.6, the suspended CHS increased ‘apparent’ solubility to 0.16 mg/mL. Release at pH 1.2 was fast for formulations with intermediate CHS and drug levels. At pH 5.6, conventional pellets showed incomplete release while mini pellets with a CHS/drug ratio ≥2 and up to 21.25% drug, showed an extended release that was completed within 8 h. Numerical optimization provided optimal formulations for fast release at pH 1.2 with drug levels up to 40% as well as for extended release formulations with drug levels of 5% and 10%. The Weibull model described the release kinetics indicating complex or combined release (parameter ‘b’ > 0.75) for release at pH 1.2, and normal diffusion for the mini pellets at pH 5.6 (‘b’ from 0.63 to 0.73). The above results were attributed mainly to the different pellet sizes and the extensive dissolution/erosion of the gel matrix was observed at pH 1.2 but not at pH 5.6.
机译:使用挤出/滚圆法和中等粘度的壳聚糖(CHS)制备了两种尺寸的吡罗昔康(PXC)颗粒(微型(380-550μm)和常规(700-1200μm))。应用混合物实验设计和数值优化来区分可生产具有快速释放或延长释放的高球形颗粒的配方。高CHS含量需要更大的润湿液体积才能形成颗粒,并且直径随体积线性减小。 CHS可提高中低药物含量的球形度。 PXRD的应用表明该药物是II型和I型的混合物。结晶度由于加工而降低,在5%的药物含量下显着。拉曼光谱显示没有相互作用。在pH 1.2时,溶解的CHS将“表观”药物溶解度增加到0.24 mg / mL,而在pH 5.6时,悬浮的CHS将“表观”药物溶解度增加到0.16 mg / mL。对于具有中等CHS和药物水平的制剂,在pH 1.2下的释放速度很快。在pH 5.6时,常规小丸显示出不完全释放,而CHS /药物比率≥2且药物含量高达21.25%的小丸显示出在8小时内完成的延长释放。数值优化为药物在pH 1.2时高达40%的快速释放以及药物在5%和10%的缓释制剂提供了最佳配方。 Weibull模型描述了释放动力学,表明在pH 1.2时复合释放或复合释放(参数“ b”> 0.75),以及pH 5.6(“ b”从0.63到0.73)时小颗粒的正常扩散。上述结果主要归因于不同的颗粒尺寸,并且在pH 1.2但未在pH 5.6观察到凝胶基质的广泛溶解/侵蚀。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号